Your browser doesn't support javascript.
loading
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Rathkey, Daniel; Khanal, Manakamana; Murai, Junko; Zhang, Jingli; Sengupta, Manjistha; Jiang, Qun; Morrow, Betsy; Evans, Christine N; Chari, Raj; Fetsch, Patricia; Chung, Hye-Jung; Xi, Liqiang; Roth, Mark; Filie, Armando; Raffeld, Mark; Thomas, Anish; Pommier, Yves; Hassan, Raffit.
Afiliação
  • Rathkey D; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Khanal M; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Murai J; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Zhang J; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Sengupta M; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Jiang Q; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Morrow B; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Evans CN; Genome Modification Core, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Chari R; Genome Modification Core, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Fetsch P; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Chung HJ; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Xi L; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Roth M; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Filie A; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Raffeld M; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Thomas A; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Pommier Y; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Hassan R; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: hassanr@mail.nih.gov.
J Thorac Oncol ; 15(5): 843-859, 2020 05.
Article em En | MEDLINE | ID: mdl-32004714
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares / Mesotelioma Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares / Mesotelioma Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2020 Tipo de documento: Article